Comparable stake leader
Nantahala Capital Management, LLC
SEC ownership of EAGLE PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000827871.
Disclosed value leader
Nantahala Capital Management, LLC
Comparable rows
6/15
Latest evidence
31 Mar 2026
- Parsed ownership sources
- 13D/G, 13F, and 3/4/5
- Largest SEC-reported holder
- Nantahala Capital Management, LLC
- Latest 13D/G holder
- Nantahala Capital Management, LLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0000827871
- Issuer location
- Woodcliff Lake, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of EAGLE PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Nantahala Capital Managem...
Disclosed value leader
Nantahala Capital Managem...
Comparable rows
6/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 38%
9 rows are not safely comparable across share classes.
13D/G row: Nantahala Capital Management, LLC
Showing 1-8 of 15 holder rows.
Quick read
Nantahala Capital Management, LLC leads the comparable SEC ownership view at 38%.
6 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Nantahala Capital Management, LLC's linked filing trail.
Comparable ownership
Top 5
Nantahala Capital Management, LLC
38%
Union Square Park Capital Managem...
11%
Nantahala Capital Partners Limite...
6.2%
J. Goldman & Co LP
5.1%
Stanley-Laman Group, Ltd.
0.09%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC |
13D/G
|
38%
|
$14,341,106
4,945,209 shares
|
$0 | 30 Jun 2025 |
| Union Square Park Capital Management, LLC |
13D/G
Union Square Park Partners, LP
|
11%
|
$2,911,927
1,485,677 shares
|
$0 | 31 Dec 2024 |
| Nantahala Capital Partners Limited Partnership |
13D/G
|
6.2%
|
$1,588,835
810,630 shares
|
$0 | 16 Feb 2025 |
| J. Goldman & Co LP |
13D/G
|
5.1%
|
$1,934,613
667,108 shares
|
$0 | 30 Jun 2025 |
| Stanley-Laman Group, Ltd. |
13F
Company
|
0.09%
|
$4,093
12,000 shares
|
— | 31 Mar 2026 |
| Archer Investment Corp |
13F
Company
|
0%
|
$119
350 shares
|
— | 31 Mar 2026 |
| Scott Tarriff |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$9,111,840
1,453,244 shares
|
— | 28 Feb 2024 |
| Brian Joseph Cahill |
3/4/5
CHIEF FINANCIAL OFFICER
|
—
class O/S missing
|
$308,850
47,958 shares
|
— | 27 Feb 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to EAGLE PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Scott Tarriff
Net 12M change
$0
Latest report
11 Nov 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Scott Tarriff | 10%+ Owner | $9,111,840 | Mixed | 28 Feb 2024 | ||
| Brian Joseph Cahill | Chief Financial Officer | $308,850 | Mixed | 27 Feb 2024 | ||
| Michael Shawn Moran | EVP, Chief Commercial Officer | $164,750 | Mixed | 28 Feb 2022 | ||
| Michael Graves | Interim Executive Chair & PEO, Director | $53,147 | Mixed | 21 Dec 2023 | ||
| Robert Glenning | Director | Mixed | 07 Mar 2023 | |||
| Christopher Krawtschuk | Chief Financial Officer | Mixed | 11 Nov 2024 | |||
| Richard A. Edlin | Director | Mixed | 07 Mar 2023 | |||
| Steven B. Ratoff | Director | Mixed | 07 Mar 2023 | |||
| Luciana Borio | Director | Mixed | 07 Mar 2023 | |||
| Jennifer K. Simpson | Director | Mixed | 07 Mar 2023 |
Recent insider transactions for EAGLE PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.